[COX6C Promotes the Proliferation of Multiple Myeloma Cells by Increasing Intracellular ATP Levels] [0.03%]
COX6C通过提高细胞内ATP水平促进多发性骨髓瘤细胞增殖
Zhi-Hua Li,Yi-Hua Wang,Wen-Hua Liu et al.
Zhi-Hua Li et al.
Objective: To investigate the effect of COX6C on the proliferation of multiple myeloma (MM) cells and its mechanism of action. Methods: ...
[Thromboelastography Combined with Blood D-Dimer in the Prediction of Lower Extremity Venous Thrombosis in Patients with Diffuse Large B-Cell Lymphoma] [0.03%]
血栓弹力图联合D-二聚体预测弥漫大B细胞淋巴瘤患者下肢静脉血栓形成的风险分析
Jiao Ge,Min Chen,Zhi-Min Shangguan et al.
Jiao Ge et al.
Objective: To investigate the predictive value of thromboelastogram(TEG) combined with blood D-dimer in patients with diffuse large B-cell lymphoma(DLBCL) complicated with venous thromboembolism(VTE) of lower extremities....
[Efficacy and Safety of Polatuzumab Vedotin Combined with Chemotherapy in the Treatment of Relapsed and Refractory Diffuse Large B-Cell Lymphoma] [0.03%]
波妥西联合化疗治疗复发/难治弥漫大B细胞淋巴瘤疗效及安全性分析
Ke-Ting Jin,Jin-Dan Xia,Chu-Yun Qian et al.
Ke-Ting Jin et al.
Objective: To observe the efficacy and safety of polatuzumab vedotin (pola) combined with chemotherapy in the treatment of relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL). ...
[Mechanistic Study of ATO and MET Synergistically Promoting Apoptosis in Leukemia Cells] [0.03%]
ATO和MET协同促白血病细胞凋亡的机制研究
Meng Liu,Li-Wen-Hui Huang,Xiao-Hui Si et al.
Meng Liu et al.
Objective: To study the mechanism of arsenic trioxide (ATO) combined with metformin (MET) in promoting apoptosis of leukemia cells. Methods: ...
[The Synergistic Anti-Leukemia Effect of Bcl-2 Inhibitor Combined with HDAC Inhibitor by PI3K/AKT/FoxO1 Axis in T-Cell Acute Lymphoblastic Leukemia] [0.03%]
Bcl-2抑制剂联合HDAC抑制剂通过PI3K/AKT/FoxO1轴协同逆转T细胞急性淋巴细胞白血病耐药性
Dan-Dan Song,Si-Yu Gu,Chun-Hua Song et al.
Dan-Dan Song et al.
Objective: To investigate the mechanism of the synergistic anti-leukemia effect of the combination of Bcl-2 inhibitor venetoclax (VEN) and histone deacetylase (HDAC) inhibitor chidamide (CDM) in T-cell acute lymphoblastic...
[Relationship between Peripheral Blood MiR-21 and Very Early Relapse after Chemotherapy in Children with Acute Lymphoblastic Leukemia] [0.03%]
急性淋巴细胞白血病儿童化疗后早期复发与外周血miR-21的关系
Le Chen,Yan Wang,Cheng-Jiao Huang et al.
Le Chen et al.
Objective: To analyze the relationship between microRNA-21 (miR-21) expression and the risk of very early relapse post-induction chemotherapy in children with acute lymphoblastic leukemia (ALL). ...
[Expression of Type 2 Innate Lymphoid Cell and IL-9 and Other Related Cytokines in Chronic Lymphocytic Leukemia] [0.03%]
慢性淋巴细胞白血病中ILC2s及IL-9等相关细胞因子的表达
Rui-Xue Yang,Rui Zhang,Xue-Jiao Zeng et al.
Rui-Xue Yang et al.
Objective: To explore the difference of type 2 innate lymphoid cell (ILC2), IL-9 and related cytokines between chronic lymphocytic leukemia (CLL) patients and normal individuals, as well as the correlation between ILC2 an...
[Clinical Characteristics and Survival Analysis of 34 Patients with Aggressive NK-Cell Leukemia] [0.03%]
侵袭性NK细胞白血病34例临床特征及预后分析
Hui-Hui Zhang,Chun-Lan Hua,Ping-Ping Sun et al.
Hui-Hui Zhang et al.
Objective: To explore the clinical characteristics and prognosis risk factors of aggressive NK-cell leukemia (ANKL). Methods: The clini...
[Efficacy and Safety of Blinatumomab in Adult Patients with B-Cell Acute Lymphoblastic Leukemia] [0.03%]
[Blinatumomab治疗成人B细胞急性淋巴细胞白血病的疗效和安全性]
Ya-Lei Hu,Yong-Feng Su,Yang Li et al.
Ya-Lei Hu et al.
Objective: To evaluate the efficacy and safety of blinatumomab in adult patients with relapsed/refractory (R/R) or measurable residual disease (MRD) positive B-cell acute lymphoblastic leukemia (B-ALL) in the real world. ...
[Analysis of Bone Marrow and Peripheral Blood Cytological Characteristics and Prognostic Research in FLT3-ITD mutated Acute Myeloid Leukemia] [0.03%]
FLT3-ITD基因突变急性髓系白血病骨髓与外周血细胞形态学特点分析及其预后研究
Hai-Bo Liu,Wen-Juan Wang,Juan Liu et al.
Hai-Bo Liu et al.
Objective: To investigate the bone marrow and peripheral blood cytological characteristics and prognosis in acute myeloid leukemia (AML) with FLT3-ITD mutation. ...